242 related articles for article (PubMed ID: 35119908)
1. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials.
Unger JM; Vaidya R; Albain KS; LeBlanc M; Minasian LM; Gotay CC; Henry NL; Fisch MJ; Lee SM; Blanke CD; Hershman DL
J Clin Oncol; 2022 May; 40(13):1474-1486. PubMed ID: 35119908
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
[TBL] [Abstract][Full Text] [Related]
3. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials.
Magee DE; Hird AE; Klaassen Z; Sridhar SS; Nam RK; Wallis CJD; Kulkarni GS
Ann Oncol; 2020 Jan; 31(1):50-60. PubMed ID: 31912796
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
6. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
Basch E; Dueck AC; Rogak LJ; Minasian LM; Kelly WK; O'Mara AM; Denicoff AM; Seisler D; Atherton PJ; Paskett E; Carey L; Dickler M; Heist RS; Himelstein A; Rugo HS; Sikov WM; Socinski MA; Venook AP; Weckstein DJ; Lake DE; Biggs DD; Freedman RA; Kuzma C; Kirshner JJ; Schrag D
JAMA Oncol; 2017 Aug; 3(8):1043-1050. PubMed ID: 28208174
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab for induction of remission in Crohn's disease.
Nelson SM; Nguyen TM; McDonald JW; MacDonald JK
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006097. PubMed ID: 30068022
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis.
Chacón MR; Enrico DH; Burton J; Waisberg FD; Videla VM
JAMA Netw Open; 2018 Dec; 1(8):e185617. PubMed ID: 30646278
[TBL] [Abstract][Full Text] [Related]
9. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy.
Bossi P; Botta L; Bironzo P; Sonetto C; Musettini G; Sbrana A; Di Giannantonio V; Locati LD; Di Maio M; Antonuzzo A
Future Oncol; 2019 Jul; 15(21):2543-2553. PubMed ID: 31240949
[No Abstract] [Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
14. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma.
Aguiar JP; Cardoso Borges F; Murteira R; Ramos C; Gouveia E; Passos MJ; Miranda A; da Costa FA
Int J Clin Pharm; 2018 Aug; 40(4):852-861. PubMed ID: 29860707
[TBL] [Abstract][Full Text] [Related]
15. Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database.
Anscher MS; Arora S; Weinstock C; Amatya A; Bandaru P; Tang C; Girvin AT; Fiero MH; Tang S; Lubitz R; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
JAMA Oncol; 2022 Feb; 8(2):232-240. PubMed ID: 34989781
[TBL] [Abstract][Full Text] [Related]
16. Eliciting adverse effects data from participants in clinical trials.
Allen EN; Chandler CI; Mandimika N; Leisegang C; Barnes K
Cochrane Database Syst Rev; 2018 Jan; 1(1):MR000039. PubMed ID: 29372930
[TBL] [Abstract][Full Text] [Related]
17. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.
Basch E; Rogak LJ; Dueck AC
Clin Ther; 2016 Apr; 38(4):821-30. PubMed ID: 27045992
[TBL] [Abstract][Full Text] [Related]
18. Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly.
Ghate SR; Li Z; Tang J; Nakasato AR
Am Health Drug Benefits; 2018 Oct; 11(7):334-343. PubMed ID: 30647822
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events.
Ip EH; Saldana S; Miller KD; Carlos RC; Gareen IF; Sparano JA; Graham N; Zhao F; Lee JW; O'Connell NS; Cella D; Peipert JD; Gray RJ; Wagner LI
Cancer; 2021 Dec; 127(24):4546-4556. PubMed ID: 34726788
[TBL] [Abstract][Full Text] [Related]
20. Age-related differences in patient-reported outcomes in patients with advanced lung cancer receiving anti-PD-1/PD-L1 therapy.
King-Kallimanis BL; Kanapuru B; Blumenthal GM; Theoret MR; Kluetz PG
Semin Oncol; 2018 Aug; 45(4):201-209. PubMed ID: 30482633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]